A neutral, evidence-rated side-by-side of Semaglutide and Retatrutide. Figures are typical reference values, not recommendations.
| Semaglutide | Retatrutide | |
|---|---|---|
| Type | Peptide | Peptide |
| Evidence level | Well established | Studied |
| Primary class | Injectable | Incretin mimetic |
| Half-life | ~7 days | ~6 days |
| Typical dose | 1–2.4 mg/wk | 4–8 mg/wk |
| Documented effects | 3 | 3 |
| Documented side effects | 2 | 2 |
A once-weekly GLP-1 receptor agonist licensed for type 2 diabetes and obesity — the drug that defined the current weight-loss era. Large, well-evidenced weight loss with a gastrointestinal side-effect profile as the main limit.
Full Semaglutide page →Retatrutide is an investigational once-weekly triple agonist acting at GLP-1, GIP and glucagon receptors. In phase-2 obesity trials it produced the largest mean weight loss reported for any incretin-based drug to date (~24% at the highest dose over 48 weeks), and it is in phase-3 development. Not yet approved for any indication.
Full Retatrutide page →